A Phase 2 Study to Evaluate Axatilimab for Hospitalized Patients With Respiratory Involvement Secondary to COVID-19

  • STATUS
    Recruiting
  • participants needed
    186
  • sponsor
    Syndax Pharmaceuticals
Send
Updated on 5 August 2020
See if I qualify
ct scan
mechanical ventilation
x-rays
coronavirus
covid-19
chest x-ray
SARS
respiratory symptoms
respiratory symptom
coronavirus infection
nasopharyngeal swab
acute respiratory syndrome (sars)

Summary

This is a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care, compared with placebo plus standard of care, in patients with respiratory signs and symptoms secondary to novel coronavirus disease (COVID-19).

Description

Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody with high affinity against CSF-1R under investigation for the prevention or treatment of respiratory signs and symptoms secondary to novel coronavirus disease (COVID-19).

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of axatilimab as an add-on to standard of care (SOC) therapy in hospitalized subjects with respiratory signs and symptoms secondary to COVID-19 compared to SOC treatment.

Eligible patients will be randomized in a 1:1 ratio to one of 2 treatment groups, active or control. All subjects will receive axatilimab or matching placebo intravenously (IV) as an add-on to SOC on Day 1, within 8 hours of randomization and on Day 15. Subjects will be followed for at least 28 days (+3 days) after the first dose of study intervention (Day 29).

The primary objective of the study is to assess the proportion of subjects alive and free of respiratory failure at Day 29.

Details
Condition ADULT RESPIRATORY DISTRESS SYNDROME, Coronavirus, Cytokine Storm, COVID, Cytokine Release Syndrome
Age 18years - 100years
Treatment Placebo, SNDX-6352
Clinical Study IdentifierNCT04415073
SponsorSyndax Pharmaceuticals
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

b'Type of Subject and Disease Characteristics'
b'Documented or confirmed SARS-CoV-2 infection by an FDA-approved PCR test of'
b'nasopharyngeal swab or stool less than 72 hours before randomization.'
b'Hospitalized for COVID-19.'
b'Illness of any duration with at least one of the following'
b'Clinical assessment (evidence of rales/crackles on exam) AND SpO2 less than or'
b'equal to 94% on room air, or'
b'Requiring mechanical ventilation and/or supplemental oxygen, or'
b'Radiographic evidence (chest x-ray or CT scan) of one of the following:'
b'Ground-glass opacities, or'
b'Local or bilateral patchy infiltrates, or'
b'Interstitial pulmonary infiltrates'
b'If the subject is intubated, must have been intubated less than 24 hours prior to'
b'randomization.'
b'Sex and Contraception Guidelines'
b'Contraceptive use by men or women should be consistent with local regulations'
b'regarding the methods of contraception for those participating in clinical studies.'
b'Informed Consent'
b'Capable of giving signed informed consent or by a designated representative which'
b'includes compliance with the requirements and restrictions listed in the ICF and in'
b'this protocol.'

Exclusion Criteria

b'Subjects are excluded from the study if any of the following criteria apply:'
b'Medical Conditions'
b'Active bacterial pneumonia defined: based on either lobar consolidation on x-ray,'
b'positive sputum cultures, or leukocytosis with a left shift.'
b'Known active tuberculosis (TB).'
b'Subjects with acquired immune deficiency syndrome (AIDS).'
b'It is not in the best interest of the subjects to participate, in the opinion of the'
b'treating Investigator.'
b'In the opinion of the investigator, progression to death is imminent and inevitable'
b'within the next 24 hours, irrespective of the provision of treatments.'
b'Female subjects who are pregnant or breastfeeding or expecting to conceive within the'
b'projected duration of the study, starting with the screening visit through 90 days'
b'after the last dose of study intervention.'
b'Excluded Prior/Concomitant Therapy'
b'Prior treatment with other agents with actual or possible direct acting anti'
b'inflammatory activity against SARS-CoV-2 in the past 30 days (e.g. chloroquine,'
b'hydroxychloroquine).'
b'Treatment with convalescent plasma.'
b'Treatment with high doses of corticosteroids (greater than 20 mg daily, prednisone'
b'equivalent) prior to randomization.'
b'Treatment with immunomodulators including anti-IL 6, anti-IL-6 receptor antagonists,'
b'or with Janus kinase inhibitors (JAKi) in the past 30 days or plans to receive during'
b'the study period.'
b'Previous exposure to study intervention or any other agent targeting CSF-1 or CSF 1R'
b'or known allergy/sensitivity to study intervention.'
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

ct scan
mechanical ventilation
x-rays
coronavirus
covid-19
chest x-ray
SARS
respiratory symptoms
respiratory symptom
coronavirus infection
nasopharyngeal swab
acute respiratory syndrome (sars)

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.